Fig. 1.

Best percentage change from baseline in target lesion size across cohorts treated with oral adavosertib

Best change in target lesion size is defined as the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction (RECIST v1.1). Forty-eight patients, who had measurable disease at baseline and at least one post-baseline scan, were included in this analysis. The three bars on the right depict: one patient with colon cancer (bid 1) who had a partial response in the target lesion but progressive disease in non-target lesions (this patient’s objective response was evaluated as progressive disease); two patients with a confirmed partial response, one had anal cancer (qd 1.2) and the other a thymoma (bid 2)

AC, adrenocortical carcinoma; ACC, adenoid cystic carcinoma